- Home
- WLY vs HRMY Comparison
WLY vs HRMY Comparison
Compare WLY & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLY
- HRMY
- Stock Information
- Founded
- WLY 1807
- HRMY 2017
- Country
- WLY United States
- HRMY United States
- Employees
- WLY N/A
- HRMY N/A
- Industry
- WLY Books
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- WLY Consumer Discretionary
- HRMY Health Care
- Exchange
- WLY Nasdaq
- HRMY Nasdaq
- Market Cap
- WLY 2.2B
- HRMY 2.0B
- IPO Year
- WLY N/A
- HRMY 2020
- Fundamental
- Price
- WLY $36.17
- HRMY $35.68
- Analyst Decision
- WLY
- HRMY Strong Buy
- Analyst Count
- WLY 0
- HRMY 9
- Target Price
- WLY N/A
- HRMY $50.56
- AVG Volume (30 Days)
- WLY 475.4K
- HRMY 942.2K
- Earning Date
- WLY 12-04-2025
- HRMY 11-04-2025
- Dividend Yield
- WLY 3.93%
- HRMY N/A
- EPS Growth
- WLY N/A
- HRMY 50.44
- EPS
- WLY 1.78
- HRMY 3.17
- Revenue
- WLY $1,670,600,000.00
- HRMY $825,944,000.00
- Revenue This Year
- WLY $0.86
- HRMY $20.68
- Revenue Next Year
- WLY $2.66
- HRMY $15.93
- P/E Ratio
- WLY $20.31
- HRMY $11.16
- Revenue Growth
- WLY N/A
- HRMY 21.13
- 52 Week Low
- WLY $32.92
- HRMY $25.52
- 52 Week High
- WLY $53.96
- HRMY $40.93
- Technical
- Relative Strength Index (RSI)
- WLY 49.35
- HRMY 74.97
- Support Level
- WLY $33.85
- HRMY $32.77
- Resistance Level
- WLY $37.37
- HRMY $36.20
- Average True Range (ATR)
- WLY 1.06
- HRMY 1.18
- MACD
- WLY 0.09
- HRMY 0.23
- Stochastic Oscillator
- WLY 72.13
- HRMY 90.45
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.